About RTX‑240 Clinical Trials

Take A Patient Screener

Participating in a clinical trial is a significant commitment.
We are grateful for the important contributions of the volunteers who take part in this important research.

About the RTX‑240
phase 1/2 clinical trial

This Phase 1/2 clinical trial is designed to establish whether RTX‑240 is safe, how much RTX‑240 needs to be given for it to be effective, and how often it should be given to be effective. The trial seeks to evaluate:

  • Any side effects associated with RTX‑240
  • Preliminary dose and schedule, meaning how much RTX‑240 needs to be given for it to be effective, and how often it should be given to be effective

All study participants
receive at no cost:

The study drug, study-related services, supplies, procedures, and care performed as part of this study and not part of your routine medical care will be paid for by the study site, through the study Sponsor.

Who can participate?

Upon reviewing the clinical trial eligibility criteria, speak with your doctor about any questions you may have and clinical trials that may benefit you.

Adults who meet the following criteria may be able to participate in the trial. We cannot guarantee all those who qualify will be selected.

For the relapsed/refractory AML arm of the trial:

  • Men and women aged 18 or older with acute myeloid leukemia that has not responded to treatment or returned following treatment (relapsed or refractory AML per protocol).
  • Participants must have completed prior therapy, including radiation, at least 28 days prior to study treatment.
  • For females of reproductive potential, agreement to use highly effective contraceptive throughout and for six months following last dose study treatment.

What to expect if you are enrolled

Screening and eligibility
(Up to 28 Days Prior to Receiving a Dose of RTX-240)

Participants in the trial will
undergo:

  • A doctor’s exam
  • Blood tests
  • Pretreatment bone marrow biopsy required
First treatment days

Patients will receive RTX-240 until the time in which the disease progresses or in the event of undesirable toxicities.

During the first week, patients will come in for the first three days, and then weekly for the rest of the cycle.

Follow-up visits

In cycle one, after the first three days, weekly visits are required.

In subsequent cycles, patients come in on day one of dosing and day three, followed by weekly visits.

Dosing days take approximately four to six hours, with subsequent visits to take approximately one hour.

Bone marrow biopsy or aspirate is required at the first two on-treatment disease assessments, and optional at the disease assessments thereafter.

Trial site locations

The Angeles Clinic & Research Institute

Los Angeles, California,

United States, 90025

 

Contact: Saba Mukarram

310-231-2181

SMukarram@theangelesclinic.org

Columbia University Medical Center       

New York, New York,

United States, 10032

 

Contact: Research Nurse Navigator

212-342-5162

Cancerclinicaltrials@cumc.columbia.edu

Massachusetts General Hospital

Boston, Massachusetts,

United States, 02114

 

Contact: Ryan Sullivan, MD

617-724-5197

rsullivan7@mgh.harvard.edu

Oregon Health & Sciences University – Knight Cancer Institute

Portland, Oregon,

United States, 97239

 

Contact: Knight Cancer Institute Clinical Trials

trials@ohsu.edu

Sarah Cannon Research Institute
Nashville, Tennessee,

United States, 37203

 

Contact: Sarah Cannon Research Site

615-329-7478

CANN.ResearchReferrals@scresearch.net

Sylvester Comprehensive Cancer Center/UMHC
Miami, Florida,

United States, 33136

 

Contact: Jaime Merchan, MD

305-243-1287

Merchan2@med.miami.edu

Virginia Cancer Specialists
Fairfax, Virginia,

United States, 22031

 

Contact: Alexander Spira, MD, PhD, FACP

703-280-5390

Alexander.spira@usoncology.com

Sarah Cannon Research Institute/ Colorado Blood Cancer Institute
Denver, Colorado,

United States, 80218

 

Contact: Sarah Cannon Research Institute

844-482-2812

asksarah@sarahcannon.com

University of California San Diego

La Jolla, California,

United States, 92093

 

Contact: Sandip Patel, MD

585-822-6477

patel@ucsd.edu

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania,

United States, 15232

 

Contact: Sarah Brodeur

412-623-2944

Brodeurs@upmc.edu

Thomas Jefferson University

Philadelphia, Pennsylvania,

United States, 19107

 

Contact: Usama Gergis, MD

215-955-4367

Usama.Gergis@jefferson.edu

RTX‑240 Phase 1/2 Clinical Trial

Complete a patient screener to see if you may be able to participate.

Patient Screener

Patient Screener

Sign up to learn more about Red Cell Therapeutics™ and cancer clinical trials.

Sign Up Form

Sign Up Form

Rubius Therapeutics is now enrolling patients in a phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors, or relapsed acute myeloid leukemia (AML) or refractory AML.

Complete a patient screener to see if you may be able to participate.

Thank you! You may be a potential candidate for a study doctor to evaluate for participation in this study.

If you wish to be connected to a clinical trial site in the RTX-240 study, please fill in your contact information below. Someone from our Patient Advocacy Team may reach out to you to determine your interest and if you would meet the requirements to be evaluated by a study doctor for screening in the RTX-240 study. Your personal information, including information entered below and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.

NEXT

Thank you!

Based on the information provided, you may not meet the requirements for this study. We want to thank you for your interest – patient volunteers and their family members are an essential part of the development of new therapies for cancer. If you still would like to learn more about Red Cell Therapeutics™ and receive updates about clinical trials that might be available in your area for the potential treatment of cancer for yourself or a loved one, sign up here.

Thank you!

You may be a potential candidate for a study doctor to evaluate for participation in this study. If you wish to be connected to a clinical trial site for the RTX-240 study, please fill in your contact information below. Someone from our Patient Advocacy Team may reach out to you to determine if you would meet the requirements to be evaluated by a study doctor for screening for the RTX-240 study. Your personal information, including information entered below and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.